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Abstract: Electronic medical records (EMRs) are used increasingly for research in clinical 
oncology, epidemiology, and comparative effectiveness research (CER).
Objective: To assess the utility of using EMR data in population-based cancer research 
by comparing a database of EMRs from community oncology clinics against Surveillance 
  Epidemiology and End Results (SEER) cancer registry data and two claims databases (Medicare 
and commercial claims).
Study design and setting: Demographic, clinical, and treatment patterns in the EMR, SEER, 
Medicare, and commercial claims data were compared using six tumor sites: breast, lung/
bronchus, head/neck, colorectal, prostate, and non-Hodgkin’s lymphoma (NHL). We identified 
various challenges in data standardization and selection of appropriate statistical procedures. 
We describe the patient and clinic inclusion criteria, treatment definitions, and consideration 
of the administrative and clinical purposes of the EMR, registry, and claims data to address 
these challenges.
Results: Sex and 10-year age distributions of patient populations for each tumor site were 
generally similar across the data sets. We observed several differences in racial composition 
and treatment patterns, and modest differences in distribution of tumor site.
Conclusion: Our experience with an oncology EMR database identified several factors that must 
be considered when using EMRs for research purposes or generalizing results to the US cancer 
population. These factors were related primarily to evaluation of treatment patterns, including 
evaluation of stage, geographic location, race, and specialization of the medical facilities. While 
many specialty EMRs may not provide the breadth of data on medical care, as found in compre-
hensive claims databases and EMR systems, they can provide detailed clinical data not found in 
claims that are extremely important in conducting epidemiologic and outcomes research.
Keywords: electronic health records, data generalizability, oncology research, health care 
claims data, epidemiology
Introduction
EMRs are being used increasingly for observational research, post-marketing safety 
evaluation, and to inform decision making.1–7 In February 2011, the Food and Drug 
Administration issued draft guidance regarding best practices for use of EMR in con-
ducting pharmacoepidemiologic studies.8 The primary advantages of EMRs include 
their potentially comprehensive and relatively timely clinical information, with the 
possibility of including physicians’ notes, patient symptoms and history, diagnos-
tic information, and planned and actual treatments. EMRs offer data not typically Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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  available in disease registries, claims records, or prescription 
databases, and are easier to analyze and usually more cost 
effective than chart reviews.
The availability of data varies across EMRs and depends 
on their design and completeness of data entry into appli-
cable fields.1 Because EMRs are designed primarily for 
patient care or billing, details that are important for health 
research (eg, tumor classification, unrelated comorbidities) 
may not be collected as rigorously as required for such 
research. Based on 2010 survey data, EMRs were adopted 
by approximately 50% of office-based physicians, increas-
ing more than 30% from 2009; however, only 10% of EMR 
systems were termed fully functional.9 Only 1.5% in 2008 
and 2.7% in 2009 of the hospitals surveyed had compre-
hensive EMR systems, defined as including different levels 
of clinical functionality (eg, clinical documentation, test/
image results) and decision support resources (eg, guide-
lines, drug alerts/interactions).10–12 EMR adoption varies by 
state9 and has occurred primarily in larger practices, urban 
areas, hospitals, or facilities owned by health maintenance 
organizations (HMOs).10,11,13
To evaluate the utility of EMRs in population-based 
cancer research, we compared demographic, clinical, and 
treatment factors from an aggregated US community oncol-
ogy clinic EMR database with three other common data 
sources: Surveillance Epidemiology and End Results (SEER) 
registry, Medicare claims, and a large US commercial health 
insurance claims database. Our primary aim was to compare 
the content and utility of an oncology EMR vs claims data 
and a cancer registry and to better understand pertinent char-
acteristics of oncology EMRs when using them to conduct 
epidemiologic and outcomes research studies. We also aimed 
to assess the benefits and results of applying data imputation 
procedures to missing data, to improve the completeness of 
data for comparison.
Methods
Data sources
The three comparison databases (SEER, Medicare, com-
mercial claims) were chosen for their high-quality data 
and rigorous data collection and processing methods. 
Numerous published studies have relied on these sources. 
In addition, groups such as the National Cancer Policy 
Board, Institute of Medicine, and others have called for 
the strategic linking, cross-validation, and evaluation of 
registry and claims data with medical records to ensure 
quality care for oncology patients. Thus, these databases 
are considered relevant for evaluation of cancer research 
applications.14–18 The most recent SEER and Medicare data 
available at the time of analysis were for 2006; therefore, 
2006 data were selected for all data sources for compara-
tive analyses.
EMr
The Oncology Services Comprehensive Electronic Records 
(OSCER) data warehouse is a proprietary database of EMRs 
from 52 outpatient oncology/hematology practice groups (15 
hospital-affiliated and 37 community office-based) operating 
at 145 clinical sites that was initially formed by merging two 
EMR systems (Varian and IMPAC) and maintained by SDI 
Health. Data records contained each patient’s diagnoses, 
clinic visits, and treatment, linked to visit dates. The inte-
grated EMR warehouse has a single structure regardless of 
EMR source and can be analyzed in a single database. While 
the site practice groups varied in completeness of various 
data fields, the two source EMR systems were comparable 
in the fields available and used for analysis.
sEEr
The National Cancer Institute’s SEER program collects 
cancer incidence data from 17 population-based registries 
representing 26% of the US population.19 SEER is considered 
a high-quality source for US cancer incidence, prevalence, 
histology, stage at diagnosis, and survival data. Except when 
compiled in special SEER studies (eg, Patterns of Care 
[POC]), prospective cancer treatment and clinical data are 
not collected from SEER-reported cancer patients.
Medicare
Medicare data, containing the claims history of about 
2 million persons sampled from 35.2 million beneficiaries, 
provided a nationally representative source of medical treat-
ment data for elderly US residents. Using the 5% sample of 
Medicare beneficiaries, we restricted the analysis to elderly 
patients ($65 years old) who were diagnosed and treated for 
cancer. Beneficiaries included those receiving care through 
traditional pay-for-service programs; those enrolled in HMOs 
were excluded.20 Diagnosis and treatment records were 
combined from inpatient (Part A), outpatient, and physician 
claims records (Part B); Part D records (pharmacy) were 
not included. Medical claims included those identified with 
diagnosis codes recorded with International Classification 
of Diseases (ICD-9-CM), and with procedural codes such 
as Current Procedural Terminology (CPT) and health care 
common procedure coding system (HCPCS) to identify 
patients of interest.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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Commercial claims
Medical information from a commercial claims database was 
used to compare the demographic and treatment data among 
cancer patients , 65 years old. These data are derived from 
approximately 14 million employees and dependents across 
various employer-sponsored health plans and self-insured 
programs per year. Data include information on services 
from all available healthcare sites (in- and outpatient, 
emergency room, physician’s office, surgery center) and all 
types of services (specialty, preventive, office-based treat-
ments). The commercial claims records included diagnosis 
codes recorded with ICD-9-CM and recorded with CPT and 
HCPCS procedural codes, as well as site of service, provider 
specialty, and revenue data. Pharmacy claims data were not 
analyzed.
Patient selection
The specific patient selection criteria for selected tumor sites 
varied slightly for each data source (Table 1). Six sites of 
primary malignancies representing those most commonly 
reported in EMR and SEER were selected: breast, prostate, 
lung/bronchus, non-Hodgkin’s lymphoma (NHL), colorectal 
(CRC), and head/neck tumors. Patients with all other forms 
of primary malignancy were grouped as “other tumors.”
EMr
Patients were $20 years old; first seen at community out-
patient oncology clinics, diagnosed with cancer between 
January 1 and December 31, 2006, and received ambulatory 
chemotherapy within 6 months of initial diagnosis (Table 1). 
To avoid classifying a patient as having cancer based exclu-
sively on rule-out diagnoses, qualifying patients had at least 
two clinic visits within a 6-month period. Patients with diag-
noses solely using V-codes (history of a particular cancer), 
tumors described as having uncertain behavior, or sarcoma 
histology codes were excluded (∼7.3% of EMR records). 
The final analytical file comprised 169,199 patient records 
with 179,046 distinct primary tumors (Figure 1) over 7 years, 
with 31,117 patients and 32,357 distinct primary tumors in 
2006. Certain clinics assigned an EMR loading date as a 
placeholder date, rather than the actual diagnosis or clinic 
visit date; these patient records were excluded.
sEEr
Equivalent exclusion criteria used in the EMR data regarding 
age and diagnosis were applied to 2006 SEER data. Cancers 
identified only from death certificates or autopsy records 
and unconfirmed cancers (no or unknown microscopic or 
histological confirmation) were excluded, as were sarcomas 
(Table 1) per SEER recommendations.21 Application of these 
criteria resulted in 20,780 patients excluded (∼5.9%). Tumor 
sites of interest were identified using the SEER-recoded 
ICD-O-3 variable, which combines ICD-O-3 site and histol-
ogy information.19
Medicare and commercial claims
Patients included those with two or more claims with the 
same cancer diagnosis in 2006 within 1 year in Medicare or 
at least 6 weeks apart in the commercial claims, and having 
no cancer diagnosis 12 months prior to the index diagnosis 
date (Table 1). To increase the likelihood of identifying new 
cancer diagnosis claims instead of prevalent conditions, 
patients were required to be covered continuously by the 
health plan or as a Medicare enrollee during the 12 months 
prior to the first cancer claim (ie, all Medicare patients were 
$66 years old). Claims only from laboratories, diagnostic 
testing centers, and diagnostic tests were not used to identify 
cancer claims, a procedure commonly used to avoid including 
false diagnoses.22–24
Factors evaluated
Patient demographic, clinical, and treatment characteristics 
were compared:
•	 Demographic: patient’s age at diagnosis, sex, and race 
were compared across all four data sources.
•	 Clinical: tumor stage was compared in the EMR and 
SEER data. Tumor stage data were not available in the 
Medicare or commercial claims data.
•	 Treatment: ambulatory treatment was compared for 
EMR, Medicare, and commercial claims data. Ambula-
tory treatment was defined as cancer treatments provided 
in a clinical or office setting and divided into chemo-
therapy, biologics, and hormones. Chemotherapy was 
defined as cytotoxic intravenous drugs; biologics as small 
molecule-targeted therapies and anything produced by 
biotechnological/recombinant methods; and hormone 
therapies were limited to injectable medications admin-
istered in the clinic. Pharmacy-dispensed medications, 
investigational drugs, and radiology treatments were 
excluded.
Ambulatory treatment in the EMR was compared to similarly 
defined treatment in the Medicare (patients $ 65 years) and 
commercial claims (patients , 65 years) databases, stratified 
by tumor site, age, and sex of the patient. Because patients can 
be treated by more than one agent, the same patient could be 
counted in different treatment groups. To better standardize Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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comparisons of ambulatory treatment usage rate, we focused 
on treatments received within 6 months of initial diagnosis.
Analytic and statistical methods
We calculated treated proportions of patients by dividing 
the number of patients receiving ambulatory therapy by the 
total number of patients with the specific cancer diagnosis. 
Given the large sample sizes from the databases evaluated, 
traditional tests of significance resulted in statistically signifi-
cant findings, even for small absolute differences. Therefore, 
we focused on descriptive comparisons and used Cohen’s w 
effect size (ES) with a pooled standard deviation to assess 
• Initial number of patient diagnoses: 1,327,510
• Initial number of patients: 263,767
• Initial number of cancer diagnoses: 353,400a
• Number of patients remaining: 220,832
• Cancer diagnoses remaining: 315,504
    (representing 237,219 distinct tumors)b
• Number of patients remaining: 213,306
• Cancer diagnoses remaining: 295,236
    (representing 227,134 distinct tumors)b
Final analytical file: 169,199 patients
179,046 distinct tumorsc
Remove
diagnoses with
sarcoma-related
histology codes
Remove
diagnoses with
problematic dates
Remove patients
with V-code only
diagnosis code
Remove patients
at EMR facilities
with problematic
diagnosis dates
Remove
patients with cancer diagnoses
prior to January 1, 2002
Remove
patients with fewer
than 2 visits
Remove
patients younger
than age 20
Remove
patients with only
diagnosis of cancer
with uncertain
behavior
Figure 1 schematic of processing and treatment of EMr oncology patient records.
Notes: For treatment analysis, EMrs without chemotherapy service and data were eliminated. Patients treated at oncology groups that did not provide chemotherapy 
services or those treated at radiology clinical sites within an oncology group were eliminated, resulting in a further reduced analytical file of 163,511 distinct tumors. athis 
was the number to which all subsequent exclusions were applied; bsome patients had multiple tumors; csome patients had multiple tumors. This file includes some pre-2006 
cancer patients that were not used.
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the importance of observed differences. This qualitative 
measure is not based on a rigorous hypothesis-testing frame-
work and does not have a probabilistic interpretation such 
as a P-value obtained from standard methods. While the ES 
interpretation depends on the subject matter, Cohen classi-
fied the magnitude of the ES as small (w = ∼0.1), medium 
(w = ∼0.30), and large (w = ∼0.50).25,26
A large proportion of data was missing for race (40%) 
and tumor stage (∼70%) in the EMR records. The largest 
percentage of missing stage data (97%) was observed for 
NHL. Given that NHL treatment is determined mainly 
by subtype and pathology (not stage), this missing data 
trend was understandable. When these two categories were 
excluded, the proportion missing for stage was 63%. Text 
fields were not analyzed to determine whether they contained 
missing stage information. We selected a hot-deck method 
to impute missing data,27 and compared this method against 
two other regression-based imputation procedures.28–30 We 
also evaluated the model prediction properties of hot-deck 
imputation by applying it to records with known values. 
Sociodemographic information (2000 US Census) was 
incorporated into the imputation models. Pre- and post-
imputation marginal distributions were compared to evaluate 
similarity in data sets and were found to be comparable to 
distributions of data among records with complete informa-
tion for race and stage. An evaluation of the performance 
of the hot-deck procedure under a simple missing data 
mechanism that compared imputed and observed data was 
also conducted. Only post-imputed data comparisons are 
presented.
Results
SEER provided the largest number of patient records 
(331,427). There were 60,255 unique records in Medicare 
and 32,357 and 16,427 records in the EMR and commercial 
claims, respectively. Several differences were observed in 
overall tumor site distributions (Figure 2). Excluding the 
“other tumors” category, the largest proportion of patients 
had prostate cancer in Medicare, and the largest proportion 
of patients had breast cancer in the other three databases. In 
the oncology EMR data, .25% of the cancer patient records 
had breast tumors – nearly 7% more than the proportion in 
SEER – while Medicare had the lowest fraction (8%). The 
EMR had the highest percentage of lung cancer and NHL 
patients; proportions of patients with CRC or head/neck 
tumors were generally comparable across all databases. 
Prostate cancer was noticeably under-represented in the 
EMR, likely because prostate cancer patients are treated 
primarily by urologists.
Demographic characteristics
The mean ages of those $65 and ,65 years in the EMR 
were 74.7 ± 6.6 years and 52.3 ± 9.2 years, respectively. 
Mean ages in Medicare (all $ 66 years) and commercial 
claims (all , 65 years) were 76.4 ± 7.2 and 51.4 ± 9.7 
years, respectively. Age distributions were similar in EMR 
and SEER, except for 1) CRC, which had a younger age 
profile in EMR patients, and 2) prostate tumors, which had 
a larger proportion of $85-year old patients in the EMR 
(Table 2). Differences in sex distributions were gener-
ally ,5%. Comparison of race was possible only for EMR 
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Table 2 Age and gender distribution of oncology EMr and sEEr patients by selected tumor site (2006 data)
Tumor site Subgroup # of qualifying  
patients in EMR
% by tumor site  
in EMR
# of qualifying  
patients in SEER
% by tumor  
site in SEER
Breast Female 8286 98.9 61,764 99.3
Male 86 1.1 438 0.7
Age group (years)
20–34 151 1.8 986 1.6
35–44 829 9.9 6603 10.7
45–54 1990 23.9 14,955 24.1
55–64 2214 26.4 15,479 24.9
65–74 1769 21.1 12,105 19.4
75–84 872 10.4 9178 14.7
85+ 547 6.5 2893 4.6
Total 8372 100.0 62,202* 100.0
Colorectal Female 1585 47.7 18,406 49.3
Male 1741 52.3 18,935 50.7
20–34 61 1.8 483 1.3
35–44 183 5.5 1699 4.5
45–54 532 16.0 5067 13.6
55–64 851 25.6 7440 19.9
65–74 870 26.2 9106 24.4
75–84 504 15.2 9502 25.4
85+ 325 9.8 4042 10.8
Total 3326 100.0 37,341* 100.0
Prostate Female 0 0 0 0
Male 1,866 100 50,934 100
20–34 1 0.1 4 0.0
35–44 3 0.2 345 0.7
45–54 93 5.0 4671 9.2
55–64 410 22.0 16,018 31.5
65–74 625 33.5 18,138 35.6
75–84 432 23.2 9977 19.6
85+ 302 16.2 1760 3.5
Total 1866 100.0 50,934* 100.0
Head and neck Female 289 26.4 2668 32.4
Male 804 73.6 5570 67.6
20–34 11 1.0 193 2.3
35–44 67 6.1 546 6.6
45–54 234 21.4 1768 21.5
55–64 325 29.7 2290 27.8
65–74 265 24.2 1742 21.1
75–84 124 11.3 1256 15.2
85+ 67 6.1 443 5.4
Total 1,093 100.0 8,238 100.0
Lung Female 2559 47.5 18,822 47.1
Male 2830 52.5 21,180 52.9
20–34 25 0.5 110 0.3
35–44 117 2.2 701 1.8
45–54 631 11.7 3890 9.7
55–64 1307 24.3 8950 22.4
65–74 1853 34.4 12,858 32.1
75–84 990 18.4 11,168 27.9
85+ 466 8.6 2325 5.8
Total 5389 100.0 40,002 100.0
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and SEER data; small differences (w , 0.15, all tumor sites) 
were observed. For each tumor site, the proportion of black 
patients in the EMR was higher than in SEER (Figure 3), 
likely because of geographic differences. The EMR groups 
were more concentrated in the South (41.2%) compared to 
SEER, which is more concentrated in western states (59.4%) 
and less in the South (10.1%)   (Figure 4). Racial differences 
varied by tumor site (Figure 3).
Clinical characteristics
Comparison of tumor stage was possible only for EMR and 
SEER data. In SEER, stage is recorded at diagnosis, whereas 
stage in the EMR could be recorded either at diagnosis or at 
first visit. Comparison of the distributions of stage I and IV 
by tumor site in EMR and SEER indicated small differences 
(w , 0.20) (Figures 5 and 6). EMR and SEER had a similar 
percentage of stage I breast cancer patients, but SEER had 
higher proportions of  stage I colorectal, head/neck, and lung/
bronchus cancer than the EMR, likely because early stages 
of these diseases rarely require the systemic therapy offered 
by oncology clinics. The EMR data had a greater proportion 
of stage IV patients recorded for breast cancer, CRC, head/
neck cancer, prostate cancer, and other cancers combined 
compared to SEER (Figure 6).
Treatment characteristics
Differences were observed in ambulatory treatment. In 
general, for all tumor sites except NHL and prostate can-
cer, a much larger percentage of patients in the EMR were 
treated compared to patients in the Medicare data (Table 3). 
This may be an artifact of age, where elderly patients with 
lower life expectancy might not be treated as aggressively as 
Table 2 (Continued)
Tumor site Subgroup # of qualifying  
patients in EMR
% by tumor site  
in EMR
# of qualifying  
patients in SEER
% by tumor  
site in SEER
NHL Female 1135 48.8 6494 46.8
Male 1192 51.2 7395 53.2
20–34 104 4.5 510 3.7
35–44 141 6.1 974 7.0
45–54 331 14.2 1975 14.2
55–64 514 22.1 2808 20.2
65–74 588 25.3 3119 22.5
75–84 366 15.7 3295 23.7
85+ 283 12.2 1207 8.7
Total 2327 100.0 13,889* 100.0
Notes: *several qualifying patients were missing age information in sEEr. The totals shown include the patients with missing information. The number of patients with missing 
information is as follows: breast cancer, 3 patients; colorectal cancer, 2 patients; prostate cancer, 21 patients; and nhL, 1 patient.
Abbreviations: EMr, electronic medical records; sEEr, surveillance Epidemiology and End results.
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other oncology patients. Among treated patients in the EMR 
and Medicare populations, EMR patients were more often 
treated with chemotherapy, except for breast cancer (Note: 
oral chemotherapy was not captured) and NHL. Patients 
in the EMR received more biologics and less hormone 
therapy than patients in the other databases, except for 1) 
lung cancer, where there were no differences in biologics, 
and 2) breast cancer, where hormones were more prevalent 
in breast cancer patients in the EMR (Table 4). Compared 
to Medicare, a much larger percentage of EMR patients 
received chemotherapy (44% vs 5%) among elderly prostate 
cancer patients. Among non-elderly patients (,65 years), the 
fraction of treated patients in the EMR was higher than in 
the commercial claims (Table 3). Differences in treatment 
Legend
EMR area
SEER area
Shared EMR and
SEER area
Figure 4 geographic distribution of oncology EMr and sEEr patients.
Abbreviations: EMr, electronic medical records; sEEr, surveillance Epidemiology and End results.
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distribution among patients treated with chemotherapy and 
hormones were generally ,5%, except in prostate cancer 
patients (Table 4). For all tumor sites except NHL, patients 
in the EMR were more likely to be treated with biologics 
than those in the commercial claims database.
Discussion
In this comparative analysis, similar distributions were observed 
in all four databases with respect to age and sex characteristics 
within specific tumor sites (w , 0.3); there were modest dif-
ferences in racial composition (#15%) and treatment patterns 
(#30%) for several tumor sites. The overall tumor site distribu-
tion varied, with more breast cancer and proportionally fewer 
prostate cancer patients in the EMR. The greater percentage of 
breast cancer patients in the EMR compared to Medicare may 
be due to the high treatment rate of breast cancer patients in 
outpatient oncology clinics and because breast cancer occurs 
at a younger median age than other cancers. Thus, while breast 
cancer survivors certainly exist in the Medicare population, the 
number of newly diagnosed patients is expected to be small. 
Prostate cancer was noticeably under-represented in this oncol-
ogy EMR, likely because these patients are treated primarily 
by urologists prior to referral to an oncologist, and treatment 
is less aggressive compared to other tumors. This limits the 
comparison of prostate cancer patients in the EMR with those 
in SEER and claims data. A large difference was observed 
among elderly prostate cancer patients in EMR compared to 
Medicare, most likely because most patients are referred to 
an oncologist after they have become hormone-refractory. 
Oncology patients in Medicare may also be less likely to be 
treated given their advanced age and decreased ability to toler-
ate aggressive chemotherapy.
Although the use of administrative data, claims-based 
databases, and other secondary data sources in epidemio-
logic research may not be ideal, they are well suited for 
certain types of analyses.31,32 Other types of data commonly 
used in epidemiologic research, such as SEER data, are also 
well suited for certain analyses, but can be problematic in 
that they may be over- or under-representative of certain 
populations. In this analysis, our approach used a combi-
nation of three different databases, including a large com-
mercial claims database, to circumvent database-specific 
issues and evaluate the utility of our EMR database from 
a broader perspective. In addition, we reported results in 
Table 3 Percent of patients receiving outpatient hormone, biologic, or chemotherapy in oncology EMr, medicare, and commercial 
claims by tumor site and age category, 2006
EMR patients  
($65 years)
Medicare EMR vs  
Medicare
EMR patients  
(,65 years)
Commercial  
claims
EMR vs  
commercial claims
% treated % treated % difference % treated % treated % difference
Breast 20.6 13.7 6.9 44.4 28.1 16.3
Colorectal 40.7 20.1 20.5 60.4 45.8 14.7
head/neck 51.1 21.0 30.0 55.1 22.1 33.0
Lung/bronchus 50.7 34.4 16.3 58.5 55.2   3.3
nhL 41.2 44.6 -3.4 47.6 38.4   9.2
Prostate 24.2 32.5 -8.3 23.1 12.8 10.3
Total1 34.8 16.1 18.6 45.9 23.7 22.3
Note: 1Total includes other cancers and the six cancers listed above.
Abbreviations: EMr, electronic medical records; nhL, non-hodgkin’s lymphoma.
Table 4 Percent of treated patients receiving hormone, biologic, or chemotherapy in oncology EMr, Medicare, and commercial claims 
databases patients by tumor site
Tumor site EMR patients $ 65 years Medicare EMR patients , 65 years Commercial claims
% C % H % B % C % H % B % C % H % B % C % H % B
Breast 85.8 10.8 22.5 91.6 3.4 20.4 94.8 5.3 23.9 95.5 4.5 16.7
Colorectal 94.6 1.6 33.3 91.1 8.1 25.7 98.4 0.1 39.8 99.6 0.2 26.7
head/neck 79.1 2.1 38.2 72.4 7.1 35.8 89.9 0.0 29.1 92.0 0.8 22.4
Lung/bronchus 98.4 0.6 11.3 97.1 3.2 11.3 99.5 0.5 14.6 99.8 0.4 10.8
nhL 72.2 0.2 83.9 79.6 1.8 78.3 85.8 0.6 74.0 88.9 0.4 80.8
Prostate 43.8 65.8 6.3 5.1 96 1.7 46.7 63.3 4.4 7.6 94.4 1.0
Total1 88.3 5.9 24 68.1 27.9 19.5 94.7 2.8 26.1 91.2 7.1 18.9
Note: 1Total includes other cancers and the six cancers listed above.
Abbreviations: C, chemotherapy; h, hormones; B, biologics; EMr, electronic medical records; nhL, non-hodgkin’s lymphoma.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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terms of relative differences (ie, effects sizes, propor-
tions or percentages) rather than absolute differences to 
facilitate interpretation inference, as recommended by 
Sorensen et al.33 The current analysis was focused solely on 
the US, mostly because the EMR data was collected from 
US oncology patients and our goal was to understand the 
generalizability of this database to the general US cancer 
population. While a similar approach could be used in dif-
ferent countries, EMR and claims-based systems will vary 
by country based on payment system; thus, this approach 
may or may not be applicable.
Many specific data comparability and methodological 
challenges arose during our analyses. These challenges fall 
into two general areas: 1) missing data and data standardiza-
tion, and 2) patient/clinic characterization. For each of these 
challenges, we evaluated several approaches and assumptions 
and developed solutions to enable comparisons. Other chal-
lenges in using EMR and claims-based data are described 
elsewhere.34,35 Data vocabulary issues were also challenging. 
For example, our classification of treatment as biologic, 
hormone, or chemotherapy was performed a priori, with 
input from oncologists and pharmacologists; however, some 
biologics may be classified differently by others.
Missing EMR data can introduce various problems in 
their validity in cancer research. In our analyses, the stage 
was frequently missing in the EMR and, though it was pos-
sibly recorded in the physician’s notes or reports, was neither 
abstracted nor recorded in the EMR stage field. Patient race 
was also frequently missing in the EMR. Evaluation of text-
based fields may result in additional data, particularly the 
stage, but was beyond the scope of this analysis, leading to 
the need for data imputation. Although imputation procedures 
were applied to fill data gaps to enable comparative analy-
ses, the selection of an appropriate imputation method and 
subsequent validation of its application were challenging, 
especially because as much as 70% of the stage data was 
missing in some cases. This was considered in selecting the 
imputation method, and results were validated in a number 
of ways to reduce bias. The imputation methods allowed 
for population-level comparisons with other oncology data; 
however, at the individual record level, our validation study 
showed that the imputed data assignment may vary con-
siderably from the true value, such that analyses that rely 
on individual-level imputed values will have errors due to 
incorrect classification.
Another challenge in data comparisons stemmed from 
patient selection, where patients from claims databases 
included all those who had at least two claims for any 
  non-diagnosing visit with a cancer diagnosis either 6 weeks 
apart (commercial claims) or within 1 year (Medicare), 
independent of physician specialty and treatment type. In 
comparison, the EMR population included any patients 
with a cancer diagnosis and at least two visits in an oncol-
ogy clinic, independent of treatment status. Since a patient 
seeing an oncologist is more likely to be treated, a much 
larger percentage of patients in the EMR received some 
type of therapy compared with the percentage in the claims 
databases, even when database tumor site distribution was 
similar. For example, for all tumor sites, except prostate 
cancer and NHL, in patients aged 65 or over, patients in 
the EMR were more frequently treated than those in other 
databases. The evaluation of treatment patterns warrants 
additional research, particularly because EMRs may aid in 
accelerating data collection and linking for evaluation of 
oncology treatment and patterns of care. Previous publica-
tions of treatment patterns15–18 have been useful in measuring 
standards of care and changes over time.
In some cases, results obtained from EMR data were 
inconsistent with claims data, particularly treatment pat-
terns. Differences in treatment patterns may be solely due 
to variance in tumor stage or to other factors, such as certain 
therapies being used more in the specialty oncology clinics. 
Differences in treatment could also be attributed simply to 
age and reduced life expectancy. From a clinical perspec-
tive, stage is usually the primary determinant of whether to 
treat (or not) a specific tumor with systemic therapy,36 so the 
absence of stage data in the EMR fields and in commercial 
and Medicare claims is problematic to the interpretation of 
observed treatment differences. Treatment in EMR patients 
was not compared to SEER, since it was not available. Future 
studies might implement SEER POC studies,37 which record 
information regarding cancer treatment reported in hospital 
and other medical records, to better understand treatment 
patterns in a national, population-based sample. Because 
outpatient treatment is often not well documented in hos-
pital records, SEER POC studies37 could aid in providing 
additional information on treatment among representative 
cancer patients. Similarly, the linked SEER-Medicare data 
files may present another source of data to better understand 
treatment and patient characteristics.
Other issues to consider in comparing findings across 
databases are selection factors that may influence treatments 
used and demographic profiles, because each database is 
derived from different populations, although some overlap 
exists. Racial differences may be explained by the fact that 
40% of EMR facilities are in the southeastern region of the Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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US, with , 25% in the West, whereas 60% of SEER regis-
tries are in western states. Commercial claims and Medicare 
patients were included without any restriction applied to 
the type of clinic or physician visited. The included EMR 
facilities were referral oncology clinics, with patients who 
were more likely to require treatment by an oncologist, who 
might in turn be more likely to adopt the latest treatment 
technologies or use more aggressive treatment. Thus, treat-
ment differences in the EMR and claims databases could be 
due to physician specialty or clinic and practice type.
There were several limitations in our analysis. We relied 
entirely on data provided in the EMR data warehouse; there-
fore, our analyses are limited to their accuracy and complete-
ness and do not account for potential errors in data entry or 
misclassification. In addition, although we made every effort 
to isolate apparently newly diagnosed cancer cases in the 
EMR, due to previous clinic treatment not being recorded in 
this EMR, it is possible that some patients were being treated 
for recurrences of disease or had been treated before. This 
could also affect how the stage was recorded. Comparison of 
the proportion of stage IV patients in EMR and SEER data 
suggests that EMR patients have later stage cancer when 
appearing for care than the patients in SEER; however, this 
may be due to the fact that the stage is recorded at diagnosis 
in SEER and at a potentially unknown time period in disease 
progression for the EMR. Another limitation is the represen-
tativeness of our EMR data with other oncology data. The 
EMR data may differ from other databases due to patients’ 
stage and disease severity and clinic/provider specialization; 
this was noted specifically for prostate cancer, where treat-
ment by urologists (rather than oncologists) providing less 
aggressive treatment might lead to under-representation of 
this tumor in the EMR population. The fact that participat-
ing clinics were willing to provide and license their data 
for analysis may reflect other differences in these patient 
populations and treatment patterns when compared to other 
oncology databases. In addition, our analysis excluded 
pharmacy-dispensed medications and claims because they 
are not fully recorded in the EMR. Because some cancers are 
now treated with prescribed oral medications,35,37 not neces-
sarily recorded in the EMR, exclusion of pharmacy claims 
data may affect treatment interpretations. Finally, our focus 
on outpatient oncologic care may prevent comparison with 
other research that includes both inpatient and outpatient 
treatment.
The limitations of the data for purposes of this analysis 
relate to the timeliness of information and the availability of 
comprehensive comparable data fields across data sources. Our 
analysis was limited to 2006, because this was the most recent 
data available for SEER and Medicare at the time of analysis. 
Although EMRs were relatively novel in 2006, our entire EMR 
system was considered robust and included 263,767 patient 
records, 1,327,510 diagnosis records, 7,549,528 visits, and 
3,828,337 records of the office-administered medications 
over 4 years. Medicare and commercial claims data represent 
administrative claims that are used primarily for insurance 
payment purposes and often lack important clinical infor-
mation to help validate medical diagnosis and define disease 
progression. Given these limitations, various assumptions 
were made and operational definitions established to define 
and extract data for analysis. Although such assumptions are 
made frequently in studies that use administrative claims data, 
and could potentially be validated by merging claims and 
EMR, their validity was not assessed here. Finally, treatment 
percentages used may have been affected by the percentage of 
patients receiving active chemotherapy treatment vs follow-up 
and non-oncology clinic treatment, and may vary between 
EMR and reference patients.
Conclusions
Health care systems that use EMRs to track patients through 
medical service settings will offer a more complete, though 
sometimes still limited, source of data within that system. 
Our goals were to evaluate an oncology EMR database in 
comparison to a large cancer registry and two claims data-
bases to characterize differences between the databases, and 
to subsequently use these comparisons to help in estimating 
characteristics in a broader target cancer population in the US. 
Our experience with an oncology EMR database identified 
several factors, including the stage, geographic location, and 
specialization of the medical facilities, that must be consid-
ered when using EMRs for research purposes or generalizing 
results to the US cancer population and for conducting epi-
demiologic research in general. While specialty EMRs may 
not provide the breadth of data on medical care, as found in 
comprehensive claims databases and EMR systems, specialty 
EMRs can provide detailed clinical data not found in claims 
that are extremely important in conducting epidemiologic 
and outcomes research.
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